Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Progesterone Resistance 1Endometrial Neoplasms 1Endometrial Hyperplasia 1

Interventions

Megestrol Acetate 4Progestins 3Tirzepatide 2Letrozole 2Biopsy 2semaglutide 1exemestane 1Tamoxifen 1Surveys and Questionnaires 1Sampling Studies 1Restraint, Physical 1Resistance Training 1Pterocarpus marsupium 1Pharmacogenomic Variants 1Observation 1Nutrition Assessment 1Metformin 1Medroxyprogesterone Acetate 1Magnetic Resonance Spectroscopy 1LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- 1Intrauterine Devices 1Hysteroscopy 1Hysterectomy 1Everolimus 1Estrogen Replacement Therapy 1Cyproterone acetate, ethinyl estradiol drug combination 1Curettage 1Blood Specimen Collection 13,5-dimethoxy-4'-hydroxystilbene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Hyperplasia × Cyproterone acetate, ethinyl estradiol drug combination × 1 year × Clear all
NCT05316935 2025-08-11

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Fudan University

Phase 2/3 Recruiting
80 enrolled
Gynecologic

Progesterone Resistance, Endometrial Hyperplasia, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡